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ABSTRACT  
 
In this paper, we analyse the introduction of genetically modified (GM) mosquitoes in 
Brazil and use this case to probe the notion of Responsible Innovation and its 
applicability to the development of new public health biotechnologies in the global 
South. OX513A, a strain of GM Aedes aegypti mosquitoes developed by the British 
firm Oxitec, has been used experimentally in Brazil since 2009, when it was imported 
into the country as a promising new tool in the fight against dengue. We discuss the 
regulatory history of OX513A in Brazil, as well as the forms of “community 
engagement” that have accompanied the release of transgenic mosquitoes. We argue 
that the conduct of a scientific research project is only part of a broader effort to 
localize insect biotechnology in Brazil, an effort that has enjoyed very visible support 
from political authorities across the country. We conclude by arguing that if the 
framework of Responsible Innovation is to have purchase on this sort of transnational 
and multifaceted innovation trajectory, it has to include at its centre a strong notion of 
political accountability. 
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1. Introduction: Extending “Responsible Innovation” 
 
The framework of Responsible Innovation seeks to chart a path of 
enhanced public accountability in the face of the uncertainties, 
ambiguities and dilemmas brought about by scientific and technological 
change. A key motivation for this endeavour is the desire to bind 
innovation processes more firmly to societal needs through an open 
practice of reflexive stock-taking on the incipient, unspoken or otherwise 
hidden values that animate technoscientific work (Owen et al. 2012; von 
Schomberg 2013; Macnaghten et al. 2014). In the governance regimes 
and academic literatures that have begun to incorporate this concept, 
Responsible Innovation is often characterised by four dimensions: 
anticipation, reflexivity, inclusive deliberation and responsiveness 
(European Commission 2012; Owen 2014; Stilgoe et al. 2013). A central 
premise of this agenda is the desirability of a more substantial and 
meaningful inclusion of societal actors in the appraisal of new scientific 
and technological options, from their inception all the way through their 
deployment (Davies et al. 2009). 
 
So far, the concept of Responsible Innovation has been theorized 
primarily in relation to scientific research or technological development 
projects sponsored by institutions in the global North. Sympathetic critics 
have noted the need to engage with a broader conceptualisation of 
innovation (de Saille and Medvecky 2016; Parkhill et al. 2013), and 
specifically with the global or transnational nature of much of 
contemporary technoscience (Anzaldo Montoya and Chauvet 2016; 
Wickson and Forsberg 2014; Blok and Lemmens 2014; Wong 2016). Yet 
relatively few studies have examined cases outside Europe and North 
America, and the literature offers little practical advice on the potential 
challenges of doing so (Chaturvedi et al. 2016; de Hoop et al. 2016; 
Voeten et al. 2014).  
  
In this paper, we explore some of the conditions that shape the 
applicability of this framework in a global South context, specifically in 
relation to the transnational development of technologies that are 
expected to address public health emergencies. Our case concerns the 
introduction of genetically modified (GM) mosquitoes in Brazil and their 
role in the fight against dengue and other mosquito-borne diseases. Since 
2009, a strain of GM Aedes aegypti mosquitoes developed by the British 
biotechnology firm Oxitec Ltd. (Oxford Insect Technologies) has been 
used experimentally in the states of Bahia and São Paulo. Aedes aegypti 
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mosquitoes are responsible for the transmission of several arboviruses, 
including dengue, chikungunya and, more recently, Zika. The strain 
developed by Oxitec, OX513A, incorporates in its genome a lethal 
transgenic construct that renders its progeny nonviable. Provided they are 
able to mate successfully with wild-type females, the release of large 
quantities of transgenic males should help supress the local mosquito 
population and reduce the rate of disease transmission. Brazil has been a 
key testing ground for this biotechnological method of vector control, 
which now appears poised for widespread use across the Americas and 
elsewhere (e.g., Alvarez 2016). 
 
The example of GM mosquitoes in Brazil offers an opportunity to explore 
how the framework of Responsible Innovation can be applied to 
technologies that straddle and connect multiple political jurisdictions and 
innovation domains. A technology first developed in an academic context 
in the United Kingdom – Oxitec was established in 2002 as a spin-out of 
the University of Oxford in order to commercialise research from the 
University’s Department of Zoology – travels to Brazil with the 
expectation that it will quickly become an effective tool of mosquito 
control at a time when the country is in the grip of a severe dengue 
epidemic. Not only must the technology in question traverse different 
political contexts, but the very nature of the innovation is in flux, as the 
OX513A strain is adapted to new environmental and biomanufacturing 
conditions (cf. Beisel and Boëte 2013; Nading 2015). This fluidity 
extends to the technology’s regulatory status: at the time of its arrival in 
Brazil there was no precedent for the controlled introduction of a 
transgenic insect in the country, let alone one that serves as the vector of 
multiple infectious diseases. This lack of precedent extended to the 
design of appropriate mechanisms for public consultation, specifically in 
and around the sites where GM mosquitoes were to be released.  
 
As we will argue, the complex and conflict-ridden trajectory of OX513A 
mosquitoes in Brazil serves to highlight the role that political 
accountability in any effective implementation of the principles of 
Responsible Innovation. By political accountability we mean the 
existence of a set of mechanisms, institutional or otherwise, that render 
open to public scrutiny and debate the rationales that actors in positions 
of political authority draw on to support certain innovation trajectories. 
These mechanisms may encompass, but are not reducible to, activities 
that seek community consent or regulatory authorization for specific 
scientific and technological projects. In fact, one of the most striking 
lessons from the history of OX513A in Brazil so far is that the 
motivations and calculations that drove political authorities to invest in 
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the development of biotechnological methods of vector control were 
never subject to the sort of reflexive appraisal that the Responsible 
Innovation framework recommends for the governance of 
technoscientific change. In particular, the processes of “community 
engagement” promoted by the sponsors of the technology neither 
encouraged inclusive deliberation nor gave rise to opportunities for 
responsiveness to public concerns on the part of innovation actors. At the 
same time, the regulatory system never explicitly reviewed public 
expectations or concerns in its assessment of OX513A mosquitoes. The 
example of GM mosquitoes in Brazil thus exemplifies the need to extend 
the notion of Responsible Innovation beyond the appraisal of individual 
research and development projects to encompass the forms of political 
reasoning that often provide these projects with their ultimate raison 
d'être.  
 
The account that follows is based on interviews with scientists and 
regulators involved in the development of GM insects and their 
introduction in Brazil, as well as on documentary research into the 
regulatory career of OX513A mosquitoes in the country. We also 
collected and analysed press and regulatory materials (in English and 
Portuguese) describing the progress of GM mosquitoes in Brazil between 
July 2010 and April 2016. 
 
 
2. The return of dengue and the birth of Projeto Aedes Transgênico 
 
Dengue reappeared in Brazil in 1986. For more than two decades, the 
country had been virtually free of the disease, the result of a vigorous 
campaign of vector control that started in the 1950s and relied heavily on 
the use of Dichlorodiphenyltrichloroethane (DDT) and other residual 
insecticides (Magalhães 2013). The dismantling of mosquito abatement 
programmes in the 1970s, combined with a rapid process of urbanization 
and growing mosquito resistance to organochloride pesticides, created 
new opportunities for Aedes mosquitoes to spread throughout the country 
and entrench themselves in population centres (Rodriguez-Barraquer et 
al. 2011).  
 
Since the late 1990s the public health burden of dengue has grown 
exponentially. Four virus serotypes have been detected in the country, 
and the incidence of haemorrhagic fevers, the most severe form of the 
disease, has grown significantly, particularly among children (Cantão 
2012). In 2014, national authorities reported 590,000 cases of dengue and 
attributed nearly 400 deaths to infection by the virus (Ministério da Saúde 
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2015). The country now presents the highest incidence rate of the disease 
in all of the Americas (WHO n.d.).   
In the absence of effective medications – there are no drugs effective 
against dengue, and the first vaccine, Sanofi’s CYD-TDV, was only 
registered in Brazil in December 2015 – the fight against the disease 
continues to hinge on the ability to suppress the mosquito vector (Pontes 
and Ruffino-Netto 1994). The 2002 National Dengue Control Program 
(PNCD) instituted locally coordinated spraying campaigns, but failed to 
dent the spread of the disease. A serious epidemic outbreak in Rio de 
Janeiro in 2008 prompted a new series of national directives that had a 
similarly limited impact on the rate of transmission.  
 
This was the context in which in 2009 Moscamed, a not-for-profit 
organisation dependent on the Brazilian Ministry of Agriculture 
(Ministério da Agricultura, Pecuária e Abastecimento), launched the 
Projeto Aedes Transgênico (PAT), a collaboration with Oxitec and 
researchers from the Universidade de São Paulo designed to assess the 
potential use of GM A. aegypti mosquitoes in Brazil. The partnership 
followed several meetings between Oxitec and Brazilian authorities, 
some of them sponsored by UK Trade and Industry (UKTI), a British 
government agency dedicated to supporting export ventures by British 
companies (GeneWatch 2012).1   
 
PAT would bring to Brazil Oxitec’s patented RIDL method for the 
genetic modification of insects. RIDL stands for ‘release of insects 
carrying dominant lethals,’ and encompasses a series of techniques for 
inserting into insect genomes mutations that cause the death of the 
organism’s offspring. The lethal mutation incorporated into the OX513A 
strain is conditional, or repressible, because the expression of the 
transgenic construct can be neutralised by feeding the mosquito the 
antibiotic tetracycline. The ability to repress the activation of the 
transgenic element allows the large-scale manufacture of modified insects 
in the laboratory, and ensures that GM specimens will not survive long 
after their release, provided they cannot find tetracycline in the 
environment.2 
 
Oxitec has promoted RIDL as an evolution of traditional insect 
sterilisation techniques, or SIT (Alphey 2002; see also Alphey et al. 
2010). SIT programmes, in operation since the 1950s, use radiation or 
chemicals to sterilise large numbers of insects, which are then released to 
reduce the wild population of the target species. With the advent of RIDL 
and other techniques of genetic modification, mosquitoes can be made 
‘sterile’ by direct manipulation of their genomes, thus allowing greater 
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specificity in the alterations introduced in the organisms. Direct genetic 
manipulation also creates new forms of traceability for the modified 
insects. The OX513A strain, for instance, contains a fluorescent marker 
gene – the DsRed2 gene from the marine coral species Discosoma – that 
facilitates the identification of transgenic specimens (cf. Lezaun 2006). 
 
Despite a tradition of SIT programmes in Brazil – Moscamed has been 
involved in insect sterilisation campaigns for the control of agricultural 
pests, most notably the Mediterranean fruit fly – the prospect of 
introducing GM mosquitoes in the country threw up some unprecedented 
challenges. When the PAT partners announced their intention to bring 
OX513A mosquitoes to Brazil, there was no obvious regulatory pathway 
for the evaluation of a transgenic organism capable of carrying and 
transmitting multiple pathogens. In September 2009, the National 
Biosecurity Technical Commission (Comissão Técnica Nacional de 
Biossegurança, or CTNBio), a governmental advisory body on 
biosecurity matters and the authority in charge of reviewing applications 
for the introduction of GM organisms in the country, began to create such 
a pathway by authorising the importation of three batches of OX513A 
eggs from Oxitec’s production facility in Abingdon, UK.3 These batches 
– each of them containing five thousand eggs – were earmarked for 
contained use within Moscamed’s ‘biofactory’ in the city of Juazeiro, in 
the state of Bahia (CTNBio 2009; see also Reis-Castro and Hendrikx 
2013). In parallel to CTNBio’s authorisation, Oxitec obtained permission 
from the UK Department for Environment, Food and Rural Affairs 
(DEFRA) to export GM mosquito eggs to Brazil for use in contained 
facilities. Because the mosquitoes were not intended for open release, the 
authorization for their international travel did not require a risk 
assessment specifically tailored to the environmental conditions of the 
importing country (Marshall 2011). 
 
This was a significant juncture in the history of insect biotechnology. 
Around the time of its agreement with Moscamed, Oxitec was conducting 
the first-ever experimental releases of GM mosquitoes, on the Caribbean 
island of Grand Cayman. This study, designed to measure the efficacy of 
the OX513A strain in reducing the density of the local A. aegypti 
population, proceeded with very little, if any, media coverage outside the 
island. Furthermore, since the Cayman Islands is a British overseas 
territory not bound by the UK’s ratification of the Convention of 
Biological Diversity, Oxitec and its Caribbean partners were exempt from 
the notification procedures concerning the transboundary movement of 
living modified organisms that are enshrined in the Convention’s 
Cartagena Protocol on Biosafety (United Kingdom Parliament 2010). The 
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releases in Grand Cayman were made public by Oxitec at the annual 
meeting of the American Society of Tropical Medicine and Hygiene held 
in Atlanta in November 2010, once the trial had been completed. Before 
the end of the year, Oxitec initiated a second set of open field releases in 
Malaysia (Subramaniam et al. 2014).  
 
The international scientific press covered the news from Grand Cayman 
at length, and the tone of the coverage was often critical of Oxitec and of 
the secrecy with which the releases had taken place. A news article in the 
journal Science noted that news of the releases had ‘taken aback 
opponents of GM mosquitoes and surprised many researchers in the field 
of genetic control of insect vectors’ (Enserink 2010). The journal reported 
unease among some of Oxitec’s collaborators, and suggested that the 
manner in which the trial had been conducted had ‘strained ties’ with the 
Bill and Melinda Gates Foundation, a key funder of research on GM 
mosquitoes. In an editorial entitled ‘Letting the bugs out of the bag,’ the 
journal Nature criticised Oxitec for conducting the first open field trial of 
the technology in a country known for its minimalist approach to 
environmental regulation, and chastised local authorities for conducting 
the experiments without proper public consultation:  
 
Efforts by the Cayman Island authorities [to inform the public about 
the nature of the releases] seem to have amounted to not much more 
than producing little-reported leaflets and a video, posted on YouTube 
and broadcast on television, which failed to say that the mosquitoes 
were genetically modified – the main concern of critics (Nature 
Editorial 2011, 39). 
 
Warning that ‘early buy-in and support from local communities’ was 
essential for the future acceptability of the technology, the editorial called 
on the scientists working on the development of GM mosquitoes ‘to 
ensure that the relevant authorities make the relevant facts available, or 
do so themselves.’ ‘So far,’ the Nature editorial concluded:  
 
GM mosquitoes and other insects have largely flown beneath the 
radar. That will change sooner or later. It is surely better that the 
scientists involved bring them to the public’s attention, rather than 
have that attention thrust upon them by others (ibid, 39). 
 
Heeding multiple calls to clarify the international regulatory context, the 
World Health Organization (WHO) announced in 2010 the forthcoming 
publication of a set of guidelines that would spell out criteria for the safe 
testing of transgenic mosquitoes, including the conditions under which 
open field releases could proceed and the ethical and public consultation 
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protocols that should accompany any such trial. It would take WHO 
another three years, however, to produce a final guidance document 
(WHO 2014). In the meantime, Projeto Aedes Transgênico would evolve 
in the absence of an agreed international framework for the assessment of 
GM insects. 
 
 
3. Demonstration trials in Bahia 
 
As the controversy over the first outdoor release of GM mosquitoes 
unfolded in the international scientific press, the partners in Projeto 
Aedes Transgênico were planning an initial open field trial in the state of 
Bahia. The trial would serve to assess the capacity of transgenic 
specimens to survive in the local environment and mate successfully with 
wild-type counterparts. It would also allow the sponsors of the project to 
calibrate the protocols for the in-time manufacturing and post-release 
monitoring of GM mosquitoes. 
 
The intention to release OX513A mosquitoes required a series of 
regulatory decisions on both sides of the Atlantic. Under the Cartagena 
Protocol on Biosafety, the transboundary movement of living modified 
organisms destined for direct introduction into the environment must 
follow an ‘advance notification’ procedure. CTNBio reviewed a request 
for release submitted by Universidade de São Paulo (USP) researchers 
and granted its authorisation in December 2010. In the UK, Oxitec 
applied to DEFRA for permission to export GM mosquito eggs intended 
for release. As part of this application, Oxitec included a document 
detailing the steps that would be taken to minimise the potential 
environmental risks posed by the liberation of GM mosquitoes (House of 
Lords 2011).4 
 
The suburbs of Itaberaba and Mandacaru in the city of Juazeiro were 
selected as the location of the releases. The choice was made in 
consultation with municipal and state-level health authorities, who 
thought residents in those areas would be “very open to new initiatives 
regarding public health and development programs” (Capurro et al. 2016: 
10365). Contrary to existing advice on this matter (Lavery et al. 2008; see 
also Ramsey et al. 2014), site selection was not preceded by any public 
consultation, nor did it seek any form of community authorisation beyond 
those provided by existing administrative bodies. 
 
Once the site of the releases had been decided, the sponsors of PAT 
launched what they described as “a vigorous and proactive community 
	 9	
engagement campaign” (Carvalho et al. 2015, p. 4). The campaign 
encompassed a diverse array of activities, including extensive media 
coverage for the project. This is how Oxitec describes these public 
outreach efforts:  
 
Community engagement remains a key component of the programme. 
This cuts across all levels of the community from national, regional and 
local stakeholders, public health and vector control agencies, and the 
resident community. Engagement with media via radio, TV and press at 
local and national level has been vital for communication to as many 
people as possible. In a country that suffers hugely from dengue, media 
interest remains high with continued, overwhelmingly positive support 
for the project from all sectors. In addition to working with the national 
regulatory system, numerous meetings and seminars have been 
organised with public health and political leaders at all levels to provide 
information and opportunity for feedback (Oxitec 2011). 
 
As the quote suggests, “community engagement” was a broad category 
that included extensive media exposure and regular contact with 
government officials and regulators. Media interest in the releases was 
indeed considerable and went well beyond local and national outlets. In 
May 2011, for instance, the trials in Juazeiro were the subject of a special 
edition of the BBC World Service’s flagship science programme 
Discovery. In September of that year, Projeto Aedes Transgênico 
occupied the front page of New Scientist. While local and international 
reports did address some of the potential risks posed by the releases and 
gave voice to Brazilian critics of the technology (such as AS-PTA, the 
Assessoria e Serviços a Projetos em Agricultura Alternativa), the 
coverage was for the most part cautiously positive. The GM mosquitoes 
were “mutant armies waging war in the wild” (Nicholls 2011). They 
represented “a revolutionary new approach” poised to deliver “a killer 
blow to the dengue-carrying mosquito” (BBC World Service 2011; see 
Bustamante 2011 for an example of critical coverage in the Brazilian 
press). 
 
The other key component of the community engagement campaign was 
direct communication with residents of the areas where the GM 
mosquitoes were being released. Members of the PAT team conducted 
extensive house and school visits to inform local residents of the purpose 
of the releases. Significantly, this component of the public outreach 
programme was carried out in parallel to the scientific work of the 
project. The extensive monitoring required by the trial – in particular the 
installation and weekly replacement of ovitraps in hundreds of houses in 
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each of the two suburbs – offered the primary occasion for discussions 
with local residents. 
[T]here is no substitute for face-to-face interaction on an individual 
basis, allowing specific questions to be addressed and for direct 
feedback and concerns to be aired. Intensive monitoring provides 
ample opportunity for field staff to discuss the project with residents 
in their homes as they survey the local mosquito population. In 
addition, dedicated teams have conducted door-to-door visits of every 
residence to discuss the project, allowing a high level of community 
engagement. These combined efforts have resulted in visits to every 
residence in the field site, often on multiple occasions, ensuring the 
highest level of community engagement possible (Oxitec 2011).  
It was clear that the sponsors of Projeto Aedes Transgênico were keen to 
avoid the sort of criticism that had been levelled against the release of 
Oxitec’s mosquitoes in Grand Cayman. It is also clear, however, that the 
model of consultation implemented during the releases in Juazeiro was 
narrow in its scope and objectives, and offered little opportunity for 
inclusive deliberation and responsiveness. Local residents were informed 
of the purpose of the releases, whether through media outlets or in face-
to-face meetings, and they had opportunities to ask questions or offer 
feedback. Yet in most cases, this information was being provided while 
the trial was already underway, and it was apparent that the essential 
parameters of the intervention – site selection, extent and purpose of the 
releases, monitoring plan – had been decided in advance of any 
meaningful public consultation and were not subject to significant 
revision or redefinition in light of local reactions. It is telling in this 
regard that, as the above quote indicates, the sponsors of Projeto Aedes 
Transgênico thought they were in a position to determine what was “the 
highest level of community engagement possible.”  
 
The limitations of the community engagement model adopted for the first 
open field trial of OX513A are particularly significant if we consider that 
the releases were receiving at the same time very visible political support 
from local, regional and federal authorities. Under growing public 
pressure to deliver effective measures against dengue, a significant 
amount of political capital was to be gained from showcasing a new 
technology in action, even if it was in the guise of a scientific trial. In 
April 2011, for instance, the governor of the state of Bahia, Jacques 
Wagner, visited the trial site and pledged his backing for the initiative.  
 
“The state government supports this initiative and believes that this is another 
way to fight dengue. For this reason the Secretary of Health, the Secretary of 
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Agriculture and the Secretary of Science and Technology are enabling ways to 
further help this work” (Moscamed 2012; translation by the authors).  
 
During the governor’s visit, the State Secretary of Health personally 
released “about a thousand mosquitoes” in Itaberaba. The support of local 
state institutions – what PAT researchers describe as the significant 
amount of “political good will” enjoyed by the project (Capurro et al. 
2016: 10365) – was not merely symbolic: the state of Bahia had agreed to 
fund all the costs of the project, including the purchase of OX513A 
mosquitoes from the UK.  
 
The releases in Itaberaba and Mandacaru concluded in the summer of 
2012. According to its sponsors, the trial had achieved a very substantial 
reduction in the number of mosquitoes in the area where OX513A males 
had been released.5 That same summer, Moscamed inaugurated a new 
facility in the city of Jacobina, south of Juazeiro, with the purpose of 
increasing the scale of GM mosquito rearing. The opening ceremony for 
this new ‘biofactory’ provided another opportunity for local and national 
politicians to show their support for the project. Among those attending 
the inauguration were the Minister of Health of Brazil, Alexandre 
Padilha, the State Secretaries of Health and Science, Technology and 
Innovation, and a representative of the federal Ministry of Science and 
Technology. At the ceremony, Mr. Padilha declared:  
 
We stimulate the development of this project and will follow it 
closely, because it promises to be an effective alternative to control 
the main urban epidemics in the country. Our expectation is to have 
this kind of technology be complementary to others [methods] to 
control dengue, and then we will be able to improve diagnostics and 
treatment. This is why we need to bet on new technologies.	6  
 
PAT was also winning plaudits from British officials. In September 2012, 
during a trade mission to Brazil led by British Prime Minister David 
Cameron, UK Trade and Investment Minister Lord Green heralded 
Oxitec’s growing operations in the country as an example of successful 
British technology abroad. “I congratulate Oxitec,” Lord Green remarked, 
“for securing new partnerships in Brazil. Getting more companies 
exporting is a crucial part of the Government’s plan for growth” (Oxitec 
2012c). 
 
Moscamed’s new production facility would be instrumental in the next 
and final phase of Projeto Aedes Transgênico, the large-scale release of 
OX513A mosquitoes in the city of Jacobina. This would be the first open 
field trial conducted in a dense urban setting in the midst of a dengue 
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outbreak, and it was to involve significantly larger quantities of 
mosquitoes – the original plan called for the release of 4 million male 
specimens per week for a period of two years.7 The releases commenced 
in June 2013, and were accompanied by a series of community 
engagement activities similar to those carried out in Juazeiro, focalised 
once again on gaining consent from residents for the installation of 
mosquito traps. In the words of a Moscamed technical consultant:  
 
We developed a plan for publicising the project with home visits, 
lectures in city schools and communication through local media 
outlets, so that the population is aware of the stages of the project and 
will be happy to open their homes to the installation of monitoring 
traps (quoted in Oxitec 2012b). 
 
In addition to door-to-door visits, the sponsors of PAT deployed a series 
of visual props, including large mascots representing A. aegypti 
mosquitoes, to convey information about the experiment – to ‘publicise’ 
it, in the words of the consultant quoted above. The truck used for the 
releases, for instance, was equipped with loudspeakers that played a 
jingle explaining the experiment to the public, announcing the trial 
literally as it was taking place. These outreach activities were carried out 
primarily by local staff – foreigners rarely talked about the project to 
local residents or the press, and there was a clear attempt to brand the 
study as a national, Moscamed-led effort. 
 
The trial in Jacobina unfolded against worsening public health conditions. 
In February 2014, the city’s mayor declared a state of emergency due to 
the growing number of dengue cases in the area. Across the country, the 
incidence of dengue would more than double in 2015 (Ministério da 
Saúde 2016). The threat posed by Aedes aegypti mosquitoes was soon 
compounded by the realisation that the species was also responsible for 
the transmission of the chikungunya and Zika viruses.   
 
 
4. Localizing GM mosquitoes in Brazil 
 
Projeto Aedes Transgênico offered Oxitec an opportunity to bring its 
technology to Brazil and adapt it to local conditions. Oxitec has discussed 
this process as being much more than an effort to export OX513A 
mosquitoes, or to transfer a ready-made technological solution to Brazil. 
PAT was, in their words, an attempt to localise insect biotechnology in 
Brazil. 
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A key part of Oxitec’s ambition is that our technology can be 
transferred into other countries such that programmes can be carried out 
locally. This not only contributes to reducing the threat posed by the 
dengue mosquito, but it also reduces the overall cost and importantly 
creates new employment. This ‘localisation’ of our technology has been 
a key feature of the Brazil collaboration. In recent months several new 
jobs have been created in Juazeiro where mass rearing, release and 
monitoring processes have been established and refined. Oxitec has 
been working very closely with Moscamed and USP to train staff and 
create a high quality local facility (Oxitec 2012a).  
 
As the quote suggests, localisation implied the adaptation of the RIDL 
method to local manufacturing conditions, a process that required the 
training of local staff and the development of adequate mosquito rearing 
protocols in local ‘biofactories’ (Carvalho et al. 2014). This process 
allowed Oxitec to expand the geographical reach of its technology, and in 
the process created new employment opportunities in the areas where 
GM mosquitoes are bred and released. 
 
Localisation also included the development of a regulatory pathway for 
GM insects in Brazil. A landmark moment in this process was achieved 
in April 2014, when CTNBio authorised the commercial release of 
OX513A mosquitoes on the basis of their ‘intrinsic safety and negligible 
environmental risk’:  
 
We may conclude…, based on the evidence submitted by [the] 
applicant, related literature and our risk assessment, that the OX513A 
Ae. aegypti mosquito poses no additional risks to the environment, 
human beings and animals when compared to the same non-GM 
species. Our opinion is thus favorable to its release (CTNBio 2014, 9. 
Translation by the authors).8  
As relevant as the decision to allow the commercial release of OX513A 
mosquitoes was the manner in which CTNBio framed the matter at hand. 
The agency was emphatic that its remit was strictly limited to the issue of 
safety, and that the best way to answer this question was by comparing 
the risks posed by mosquitoes of the OX513A strain to those posed by 
wild-type specimens of A. aegypti. Questions about the efficacy of GM 
insects as an effective tool for the control of dengue, CTNBio noted, 
where outside the scope of its inquiry and belonged instead to political 
authorities at the state and federal level:  
 
[T]his opinion does not focus [on] issues of technological efficacy, 
costs and advantages/disadvantages as against other technologies of 
Aedes aegypti population control. Finally, questions directly linked to 
dengue control do not concern CTNBio, but the [Federal] Ministry of 
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Health and the [State] Secretariats of Health that may decide to adopt 
the technology to control this endemic disease (CTNBio 2014, 9. 
Translation by the authors). 
The rhetorical demarcation of a narrow domain of safety, and its 
separation from questions of technological efficacy, economic efficiency, 
or political legitimacy is a common strategy of regulatory agencies tasked 
with the governance of GM organisms (Jasanoff 2011; Hartley 2016; 
Lezaun 2011). The decision to determine the question of safety on the 
basis of a direct comparison with the risk profile of a conventional or 
non-GM variety of the organism under review is also a classic example of 
the application of the principle of substantial equivalence to the 
assessment of biotechnological life forms (Levidow et al. 2007). 
 
Yet in the context of the introduction of GM mosquitoes in Brazil such a 
narrowly framed assessment had significant ramifications. For one, it 
implied that the OX513A strain ought to be evaluated as a discrete and 
self-standing technology, rather than in terms of the balance of costs and 
benefits that GM mosquitoes would introduce within the broader effort to 
control dengue. An assessment of cost-effectiveness would have required 
a comparison with alternative approaches to mosquito control and dengue 
prevention, including a consideration of their potential interactions. Since 
CTNBio refused to examine this question, there was no regulatory venue 
for a public appraisal of how the introduction of GM mosquitoes might 
impact traditional measures of personal protection, for instance, or the 
sort of spraying and habitat-reduction campaigns that had been used so 
successfully in the 1960s and 1970s (cf. Lezaun and Porter 2015; see also 
Lezaun and de Koning 2015). 
 
Furthermore, CTNBio’s decision elided a factor that, as we have seen, 
had been essential to the progress of the technology, namely the very 
significant and very visible amount of political support GM mosquitoes 
were receiving from public officials. CTNBio’s ruling explicitly indicates 
that responsibility for the decision to promote the technology as an 
effective means of dengue control lies elsewhere. Yet, by reducing the 
issue of safety to the risks directly and ‘intrinsically’ posed by GM 
mosquitoes, and by abstaining from any evaluation of the reasons used to 
justify this approach to dengue control in the first place, CTNBio’s 
framing of regulatory action foreclosed an opportunity to review these 
rationales in a publicly accountable manner.    
 
Once CTNBio issued its decision on OX513A, the only missing piece of 
the regulatory puzzle was the final commercial registration of GM 
mosquitoes, which would have to be provided by the Brazilian National 
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Health Surveillance Agency (Anvisa), the governmental body responsible 
under the Brazilian Biosafety Law of 2005 for the registration and 
commercial supervision of GM organisms with direct implications for 
human health. Anvisa’s involvement in the regulation of OX513A 
mosquitoes implied that they would be considered a medical technology. 
This had important implications: the remit of Anvisa’s evaluation was 
broader than CTNBio’s, and would include not only the ‘intrinsic safety’ 
of the transgenic organism in question but also its effectiveness as a 
public health intervention.  
 
Pending a commercial registration, however, Oxitec was still able to 
carry out further releases, provided these could be construed as part of a 
scientific project and were subject to the level of supervision appropriate 
to research activities with transgenic organisms. In July 2014 Oxitec 
opened its own production facility in Campinas, in the state of São Paulo, 
and gained the capacity to produce transgenic mosquitoes without the 
collaboration of Brazilian partners. That same year, Oxitec announced a 
new project in the city of Piracicaba, not far from Campinas. Known as 
the ‘Friendly Aedes aegypti’ initiative (A. aegypti do Bem), this was the 
first partnership between the company and a local authority. It involved 
the release of large numbers of GM mosquitoes in the neighbourhood of 
CECAP/Eldorado, one of the areas of Piracicaba with the highest 
incidence of dengue.  
 
The trial in Piracicaba was initially delayed by initiatives from several 
civil society organisations. The Conselho Municipal de Defesa do Meio 
Ambiente (Comdema) requested the suspension of the releases until 
Oxitec and the municipality were able to provide conclusive evidence 
that they would entail no risk to human health or the environment.9 In 
parallel, the Society for the Protection of the Environment (SODEMAP), 
a non-governmental organization that includes among its members 
several researchers from the Universidade de São Paulo and former 
members of CTNBio, submitted a civil action to the office of the Public 
Prosecutor in Piracicaba demanding an official and impartial evaluation 
of the data submitted by Oxitec to the municipal authorities as part of its 
application to release GM mosquitoes in the city. The two initiatives were 
evidence that, by 2015, GM mosquitoes had become a matter of visible 
public concern in Brazil, and that some civil society organisations 
expected greater independent scrutiny of the conditions under which open 
field trials were being conducted.10 
 
The releases in Piracicaba eventually commenced in April 2015, and 
were accompanied by an information campaign conducted jointly by 
	 16	
Oxitec and the municipal authorities. In the words of Piracicaba’s 
Secretary of Health:   
 
During this period, municipal health workers and the Oxitec team visited a 
good proportion of the homes in CECAP/Eldorado talking about the ‘Friendly 
Aedes aegypti’ and reinforcing the importance of people continuing to 
eliminate breeding sites, keep their houses clean and follow the guidance of 
the municipal officials to avoid the proliferation of the mosquito that transmits 
dengue and chikungunya (Oxitec 2015). 
 
The project partners also commissioned a survey of local residents. The 
data showed overwhelming support for the initiative (“92.7% of 
Piracicaba citizens support the use of innovative tools to combat dengue 
and 88.5% support the use of the ‘Friendly Aedes aegypti’”).11 In the 
summer of 2016, local authorities reported a 91% drop in the number of 
cases of dengue registered in CECAP/Eldorado since the start of the 
releases, and announced an extension of the trial to 11 downtown 
districts, an area comprising over 60,000 residents (Oxitec 2016).  
 
Importantly, the trial in Piracicaba became the highest-profile open field 
experiment with GM mosquitoes – in Brazil or anywhere in the world – 
at the very moment when the public health impact of the Zika virus was 
becoming apparent. Oxitec and the municipal authorities were keen to 
showcase the ‘Friendly Aedes aegypti’ project as an exemplar of what 
biotechnological methods of vector control could accomplish in the fight 
against this new scourge. Piracicaba soon became a destination for 
journalists from around the world willing to report on ‘the front lines’ in 
the ‘war against mosquitoes’ (Sifferlin 2016; see also Pollack 2016).  
 
The new threat of Zika energized arguments in favour of insect 
biotechnology in Brazil, and mobilized further institutional support for 
GM insects. In February 2016, the President of Brazil, Dilma Rousseff, 
visited the facilities of Moscamed in Juazeiro. During her visit, the 
president of Moscamed, Dr. Jair Virginio, emphasised the “proven” 
quality of the technology:   
 
We have proven results on the technology of transgenic mosquitoes related to 
the project developed by Moscamed, including monitoring, public awareness 
(communication of project milestones), release of mosquitoes on the basis of 
the geography of the study area, climatic factors, and finally the presentation 
of results achieved to public institutions and to the community in general. 
(Quoted in Moscamed 2016. Translation by the authors). 
 
In April 2016, Anvisa granted Oxitec a special temporary registration 
(Registro Especial Temporário) authorising further research-related uses 
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of OX513A across Brazil. Under the conditions set in this license, Oxitec 
and any public authority sponsoring the use of GM mosquitoes were still 
under the obligation to monitor all releases and to submit data to 
ANVISA on a regular basis. A final commercial registration awaited 
further scientific evidence and the development of an appropriate 
regulatory framework (Lopes 2016). 
 
Yet, the Zika outbreak  also brought unexpected complications to the roll-
out of GM mosquitoes in the country. In late 2015, messages and 
postings began to circulate in social media linking the sudden emergence 
of the new disease to past releases of GM mosquitoes in Bahia and São 
Paulo. Scientific experts were quick to dismiss the alleged connection, 
but the wide circulation of these rumours raises questions about the 
effectiveness of past (and future) community engagement efforts. As GM 
mosquitoes acquire a higher public profile in the country, not least as a 
result of the vigorous promotion of insect biotechnology by political 
authorities, the design of processes of inclusive deliberation and mutual 
responsiveness has become an increasingly complex and critical affair. 
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6. Discussion 
 
Since the launch of Projeto Aedes Transgênico in 2009, the introduction 
of OX513A mosquitoes in Brazil has invoked many different forms and 
meanings of ‘innovation.’ In public presentations, and particularly in the 
international scientific press, PAT was often construed as a scientific 
endeavour, a research project geared towards the production of more 
evidence on GM mosquitoes and their capacity to suppress local vector 
populations. A small but telling example of this particular construction is 
the fact that the leading partner in all the applications submitted to 
CTNBio was always an academic institution, the Instituto de Ciências 
Biomédicas da Universidade de São Paulo, and that these submissions 
defined the proposed use of GM mosquitoes as a scientific undertaking 
designed to produce new data. The criteria used by Brazilian and UK 
agencies to authorise the arrival and initial development of OX513A 
mosquitoes in the country were those pertaining to the safe conduct of a 
scientific experiment. In the absence of a final commercial registration, 
OX513A mosquitoes continue to be released in Brazil under the terms of 
a temporary research licence. 
 
Other actors, however, have consistently presented PAT as a technology 
development project, an effort, supported by state institutions, to adapt a 
novel genetic vector control method to the specific conditions of Brazil. 
This adaptation involved the transfer of technical skills and production 
capacities from the UK, a process that Oxitec viewed as an opportunity to 
extend its operations and products into a promising new market and that 
many in Brazil saw as the starting point for a national infrastructure of 
insect biotechnology. Early questions about Oxitec’s willingness to 
license the technology to its Brazilian partners suggest that this particular 
innovation trajectory was beset from the start with conflicts about the 
scope and benefits of the partnership.  
 
Simultaneously, PAT represented to its sponsors a marketing opportunity, 
a way of advertising the potential of the OX513A strain as an effective 
tool against dengue and other mosquito-borne diseases. This marketing 
effort overlapped to a significant degree with the “community 
engagement” campaigns launched alongside the open field trials. These 
campaigns sought to inform relevant stakeholders and residents of the 
trial sites of the purpose of the releases and their intended benefits. The 
interest of Brazilian and foreign news organisations in the experimental 
releases carried out in Brazil transformed the country into the global 
testing ground for Oxitec’s technology, and for genetic methods of vector 
control more generally. Much of what the world knows today about the 
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use of GM mosquitoes as a method of disease control is based on the 
experience of OX513A in Brazil.  
 
Last but not least, PAT was also a process of regulatory innovation, a 
largely successful attempt to chart a pathway for GM mosquitoes through 
the Brazilian regulatory system in the absence of international rules or 
guidelines for their oversight and evaluation. In this regard, OX513A has 
served as a trailblazer for future insect biotechnology applications, 
including those in the area of agricultural pest control, where the largest 
market potential of the technology lies. CTNBio’s decision to assess the “intrinsic safety” of OX513A mosquitoes on the basis of a comparison 
with wild-type A. aegypti counterparts, and the procedural exclusion from 
the agency’s remit of questions of cost-effectiveness, represent a far-
reaching precedent for the future regulation of GM insects in the country. 
 
All these innovations are bundled together in the recent history of 
OX513A mosquitoes in Brazil. The element that links them all together, 
the factor that enabled GM mosquitoes to gain a foothold in Brazil and 
that explains their progress over the last seven years, is the remarkable 
degree of support that Projeto Aedes Transgênico received from political 
authorities at the local, state and federal levels. The dengue emergency 
made GM mosquitoes particularly attractive to political leaders; a great 
deal of political capital was invested in the successful introduction of 
OX513A mosquitoes, and a significant amount of political capital was 
gained from showcasing this technology in action, even in an 
experimental form, at a time when the country appeared to have no 
effective tools to halt the spread of the disease. The discovery of the 
chikungunya virus in 2014, and of Zika in 2015, only enhanced the 
promissory value of biotechnological methods for the control of A. 
aegypti. 
 
Yet these political calculations have remained under-scrutinised, a 
behind-the-scenes force that has rarely been subjected to public inquiry. 
The significant amount of media interest in OX513A mosquitoes and the 
multiple programmes of “community engagement” undertaken during the 
open field releases served primarily to “publicise” the releases, rather than 
to examine the fundamentally political choice to pursue a 
biotechnological strategy of vector control, or to explore the conditions of 
public acceptability prior to a decision to deploy the technology. In other 
words, the processes by which the sponsors of PAT and subsequent 
projects sought to obtain a degree of community consent to the release of 
GM mosquitoes were not meant to clarify, articulate or evaluate the 
reasons political authorities had to put their weight behind the technology 
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in the first place, nor did they create a venue for collective deliberation on 
its implications. Growing pressure from civil society organisations 
eventually found a venue of independent review in the office of the 
Public Prosecutor, the Ministério Público, which has become to play a 
key role in the evaluation of open field trials and their impact on the 
public interest.12 
 
This is why, in our opinion, the concept of Responsible Innovation needs 
to be more closely interlinked with a strong notion of political 
accountability. Political decisions create the conditions of possibility for 
specific innovation trajectories, within which discrete research and 
development projects then unfold. The ability to scrutinise these 
decisions determines whether and how core ideas associated with 
Responsible Innovation, such as inclusive deliberation or responsiveness, 
are adopted by innovation actors and, if so, to what effect. The still 
inconclusive history of OX513A mosquitoes in Brazil suggests that we 
need to consider more carefully how the calculations that lead political 
authorities to support specific innovation trajectories can themselves be 
subject to processes of anticipation, reflexive learning, and inclusive 
deliberation. 
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1 The partnership was initially going to include the Oswaldo Cruz Foundation 
(Fiocruz), the preeminent public health research organisation in the country. 
Ultimately, however, Fiocruz would decide not to participate, citing concerns about 
Oxitec’s reluctance to transfer the technology to its Brazilian partners. Interview with 
Fiocruz scientist, 23 March 2016. 
2 The possibility that GM mosquitoes will find tetracycline in the environment has 
been one of the controversial elements of the technology (see for instance Friends of 
the Earth, 2012). 
3 Part of the Federal Ministério da Ciência e Tecnologia (now the Ministério da 
Ciência, Tecnologia, Inovações e Comunicações), CTNBio is composed of 27 
members, including 12 scientists, 9 officials from government ministries, and 6 
representatives of civil society from the following sectors: occupational health, family 
agriculture, biotechnology industry, consumer representatives, health industry and 
environment protection NGOs. For an analysis of CTNBio’s decision-making process 
in relation to GM plants, see Braña et al (2012). 
4 The risk assessment document included in the notification is available at 
https://bch.cbd.int/database/record.shtml?documentid=105833 9last accessed 28 
September 2016). It was only submitted to the Cartagena Protocol’s Biosafety 
Clearing House in August 2014 (GeneWatch 2015).  
5 PAT reported a reduction of 95% in the number of adult A. aegypti mosquitoes in 
the area (Carvalho et al 2015). 
6 Bárbara Semerene, “Mosquito transgênico combaterá a dengue.” Available at  
http://femetopsaude.blogspot.com.br/2012/07/inovacao-mosquito-transgenico-
combatera.html (Last accessed 28 September 2016). 
7 There was an element of regional politics in the choice of location for the study. One 
of our interviewees, a former member of CTNBio, suggested that resistance to the 
releases in the northeastern part of the country, where Jacobina is located, would be 
lower than in the south. 
8 Two members of the Commission issued a dissenting opinion warning of the public 
health and environmental risks that could arise if the ecological niche currently 
occupied by A. aegypti were to be occupied by Aedes albopictus mosquitoes, an 
alternative vector of dengue. This dissenting opinion also noted ‘the failure to comply 
with existing legislation; the lack of assessment protocols appropriate to the risk 
analysis concerning flying insects; the insufficient character of the studies presented, 
and the absence (in Oxitec’s application) of the final results of field studies approved 
by CTNBio’ (CTNBio 2014, p. 10. Translated by the authors). 
9 The president of the Conselho, Sônia Cristina Ramos, stated some of the concerns 
that prompted the request: ‘Would not the mosquitoes in fact breed offspring that can 
transmit diseases? Would it not be the case that the dengue virus will modify itself 
and start demanding ways to combat the disease that will be even more complicated? 
We believe that questions like these should be answered. If there are no risks, 
Comdema will not be against the liberation of transgenic mosquitoes.’ See ‘Conselho 
quer barrar liberação de "Aedes transgênico" em Piracicaba’, globo.com (11 March 
2015). Translated by the authors. 
10 The review of the Public Prosecutor concluded with the decision to authorise the 
releases, on the condition that local residents were able to continue to use insecticides 
and other methods of mosquito control. 
11 The figures are mentioned in an article in globo.com (see Carvalho 2015), which 
quotes Oxitec (Oxitec 2015).	
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12 The story of OX513A mosquitoes in Brazil unfolded at a time of significant 
institutional turmoil in the country, when questions of political accountability were 
often at the forefront of public debate. This period culminated (as of September 2016) 
with the impeachment and removal of President Rousseff on charges of manipulating 
government accounts. 
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